PATIENT-DERIVED TUMOR XENOGRAFTS IN HUMANIZED NSG TM MICE: A MODEL TO STUDY IMMUNE RESPONSES IN CANCER THERAPY

Transcription

1 PATIENT-DERIVED TUMOR XENOGRAFTS IN HUMANIZED NSG TM MICE: A MODEL TO STUDY IMMUNE RESPONSES IN CANCER THERAPY Rick Huntress Senior Manager for Business Development The Jackson Laboratory

2 Humanized Tumor-Bearing NSG TM Mice: The Next Step in Cancer Modeling NOD.Cg-Prkdc scid Il2rg tm1wjl /SzJ (NSG) (005557) 2

3 Coordination Across Multiple Campuses Model Refinement Genome Informatics In Vivo Efficacy Services Platform Production PDX Resources CLIA-certification JAX Clinical Genomics Medical Informatics CLIA-certified Targeted exome sequencing 3

4 Hu-NSG TM & PDX Capabilities Hu-NSG TM Portfolio CD34+ cell, BLTs and custom stem cells NSG, NSG-S and other cytokine expressing NSG derivatives PDX Experience Over 300 PDX tumors all P5 or earlier Hands on experience Humanization done in house PDX work done in house We share our data with you Access options Delivery of models humanized mice with or without tumors Execution of studies 4

5 Quality Control All mouse engraftment and dosing done in ABSL2 labs and biosafety hoods All PDX donor tumors used for each passage are confirmed as human by Ki67 staining All Hu-NSG TM confirmed at >25% CD45+ prior to shipping Any mice shipped to collaborators have fecal testing for bacterial contaminates prior to shipping 5

6 IMMUNOTHERAPEUTIC DEVELOPMENT The Need for Humanized PDX Models

7 Immuno-Oncology Immune checkpoint molecules play key roles in regulating T-cell responses Programmed cell death protein 1 (PD1) Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) Immune checkpoint inhibitors represent an area of great interest in anti-cancer drug development 7

8 Many Checkpoint Inhibitors in the Development Pipeline 8

9 PDX in Hu-CD34 NSG TM Mice: Establishing Parameters; Iterative Approach What is the influence of HLA matching Will tumors be rejected if not HLA matched to the engrafted immune system Timing the Implantation of PDX/Cell Lines Before or after the human immune cells appear? Response to SOC (direct acting molecules) Different in the humanized and non-humanized NSG? Immuno-modulation via PD-1 and CTLA-4 Do immuno-modulators impact tumor growth in hu-nsg TM CD34 +? 9

10 NSG TM Mice: The perfect host for building an immuno-oncology platform No Mature B Cells No Mature T Cells No Natural Killer Cells No Complement Defective Dendritic Cells Defective Macrophages Low Incidence of Lymphoma Median Survival >89 Weeks 10

11 Experimental Timeline Whole body irradiation Tail vein injection Human B cells appear Human T cells appear 24~48 hours3 weeks 12 weeks 8 weeks 15 weeks 12 weeks 11

12 JAX Approach: Efficacy Studies in Hu-CD34 NSG TM Mice CD34 HSC NSG TM Humanized NSG TM PDX Tumor/Cell Line Humanized NSG TM with Tumor (human immune system and human tumor) 12

13 JAX Data Recapitulation of Expected PDX Growth Rates does not require HLA-type matching 13

14 JAX Data Temporal Evaluation of Engraftment on Tumor Growth in Hu-CD34 NSG TM Mice Study Design SKOV3 ovarian cancer cells (5x10 6 ) were inoculated 2 or 12 weeks post human CD34 cell injection Body weight & tumor volume were monitored twice per week for 50 days Peripheral blood collected at the end of study. Analyzed for human CD45 + donor cell engraftment 14

15 JAX Data Timing of Cancer Cell Line Engraftment, Relative to Humanization, Has No Significant Impact on Growth of SKOV3 Ovarian Cells Non HLA-matched 15

16 % of hcd45+ cells JAX Data: Timing of Cancer Cell Line Engraftment Has No Significant Effect on CD45+ Cell Population 80 hcd45+ Cells (%) in Peripheral Blood at 50 Days post SKOV3 Cancer Cells Inocaulation wks 12 wks Time of SKOV3 Inoculated after human CD34+ cell injection Not HLA matched 16

17 JAX Data: Humanization Has No Significant Impact on PDX Growth Kinetics No HLA match test Fresh tumor tissue engraftment 100% take rate in NSG TM or Hu- NSG TM mice No difference between NSG TM & Hu-NSG TM mice on tumor growth curve HuCD45+ more than 20% 17

18 % of hcd45+ cells 2.0 JAX Data: Human CD45+ Cell Percentage of the Total Tumor Population in Hu-NSG and NSG Mice HuCD45 + in BR0744 Tumor Hu-NSG NSG

19 JAX Data: Human Lymphocyte Percentage of the Total Infiltrating CD45+ in Three Hu-PDX Tumor Models

20 JAX Data: Hu-CD34 NSG TM PDX Mice are Functional Platform for Evaluating Drug Efficacy Fresh tumor tissue engraftment HuCD45+ more than 20% Avastin and 5-FU Inhibit Colon PDX Growth in hu-cd34 NSG TM PDX Mice 20

21 PDX in Hu-CD34 NSG TM Mice: Establishing Parameters; Iterative Approach What is the influence of HLA matching Tumors are not rejected in mismatch Timing the Implantation of PDX/Cell Lines Both options appear viable Response to SOC (direct acting molecules) Expected responses Immuno-modulation via PD-1 and CTLA-4 Do immuno-modulators impact tumor growth in hu-nsg TM CD34 +? 21

22 IMMUNOMODULATION OF A PD-L1+ BREAST CANCER CELL-LINE Validation of the hu-cd34 NSG TM cancer platform

23 JAX Data: Keytruda and Cisplatin Inhibit the Growth of MDA-MB-231 Tumor Model in Hu-CD34 NSG TM Engrafted with 5x10 6 cells/mouse s.c. with matrigel HuCD45+ more than 25% MDA-MB-231 cell surface expression of PD-L1: 94.3% 23

24 JAX Data: Human T Cells and B Cells Are Present in the Peripheral Blood of Hu-CD34 NSG TM MDA-MB-231 Mice 24

25 JAX Data: Human T Cells Are Present in the Tumor Tissue of Hu-PDX MDA-MB-231 Mice 25

26 IMMUNOMODULATION OF A PD-L1+ BREAST CANCER PDX MODEL Validation of the hu-cd34 NSG TM PDX platform

27 JAX Data: Keytruda and Cisplatin Inhibit Growth of the BR1126 PDX Model in Hu-CD34 NSG TM PDX Mice Fresh tumor tissue engraftment HuCD45+ in Hu-NSG mice: >25% BR1126 PD-L1 surface expression: 56.9% 27

28 JAX Data: Human T Cells and B Cells Are Present in the Peripheral Blood of Hu-CD34 NSG TM PDX BR1126 Mice 28

29 JAX Data Human T Cells and B Cells in the Tumor Tissue of Hu-CD34 NSG TM PDX BR1126 Mice 29

30 JAX Data: Efficacy Results of Keytruda +/- Docetaxel on LG1306 PDX tumors in Hu-NSG Mice Fresh tumor tissue engraftment HuCD45+ more than 20% LG1306 PD-L1 surface expression: 89.1% 30

31 Preliminary Findings and Conclusions Recapitulation of expected PDX growth rates does not require HLA-type matching Timing of engraftment does not appear to significantly impact growth kinetics Hu-CD34 NSG TM Mice demonstrate immune-cell infiltration Hu-CD34 NSG TM PDX and Cell-line platforms induce an anti-tumor response to immuno-therapeutic agents 31

32 Future Studies HLA matched versus non-matched Comparisons of T cell infiltration Evaluation of entire hu-cd34 NSG TM Platform CD34+ -engrafted versus BLTs in NSG TM New variants of NSG TM including NSG-SGM3 Mechanism of action of Keytruda in hu-cd34 NSG TM PDX and cell line models NSG TM vs hu-nsg TM Deplete CD8 cells 32

33 Collaborators JAX In Vivo Pharmacology Services James Keck, Minan Wang, Mingshan Cheng and Danying Cai JAX Genomic Medicine Karolina Palucka JAX Mammalian Genetics Lenny Shultz, Carol Bult, Susie Airhart and Ed Liu UMASS Dale Greiner and Mike Brehm 33

34 QUESTIONS?